Smallpox subunit vaccine - Regalen/National Center of Biotechnology

Drug Profile

Smallpox subunit vaccine - Regalen/National Center of Biotechnology

Latest Information Update: 17 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CNB; Regalen
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Smallpox

Most Recent Events

  • 13 Sep 2005 Galencia Pharmaceuticals is now called Regalen Inc
  • 28 Sep 2004 Galenica Pharmaceuticals has been acquired by Australian Cancer Technology
  • 14 Feb 2003 Preclinical trials in Smallpox in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top